227 related articles for article (PubMed ID: 7787324)
1. Acromegalic gigantism with low serum level of growth hormone and elevated serum insulin-like growth factor-I.
Miyazaki R; Yoshida T; Sakane N; Yasuda T; Umekawa T; Kondo M; Shimatsu A; Hizuka N; Sano T
Intern Med; 1995 Mar; 34(3):183-7. PubMed ID: 7787324
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone (GH) secretory dynamics in a case of acromegalic gigantism associated with hyperprolactinemia: nonpulsatile secretion of GH may induce elevated insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels.
Yoshida T; Shimatsu A; Sakane N; Hizuka N; Horikawa R; Tanaka T
J Clin Endocrinol Metab; 1996 Jan; 81(1):310-3. PubMed ID: 8550769
[TBL] [Abstract][Full Text] [Related]
3. [Gigantism with low serum level of growth hormone: a case report].
Ran X; Zhang L; Xiong P; Zhao T; Tong N; Li X
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):621-3. PubMed ID: 12528568
[TBL] [Abstract][Full Text] [Related]
4. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
[TBL] [Abstract][Full Text] [Related]
5. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
van der Lely AJ; Harris AG; Lamberts SW
Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
[TBL] [Abstract][Full Text] [Related]
6. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy.
Ho KY; Weissberger AJ
Clin Endocrinol (Oxf); 1994 Jul; 41(1):75-83. PubMed ID: 8050134
[TBL] [Abstract][Full Text] [Related]
7. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
8. Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor.
Ezzat S; Ezrin C; Yamashita S; Melmed S
Cancer; 1993 Jan; 71(1):66-70. PubMed ID: 8416728
[TBL] [Abstract][Full Text] [Related]
9. Bioactive GH-like immunoglobulins G in active acromegaly: response to long-term treatment with bromocriptine.
Campino C; Szecowka J; Lopez JM; Seron-Ferre M
Clin Endocrinol (Oxf); 1995 Jul; 43(1):111-6. PubMed ID: 7641402
[TBL] [Abstract][Full Text] [Related]
10. [The place of insulin-like growth factor I in the diagnosis of acromegaly].
Dohán O; Góth M; Szabolcs I; Kovács L; Kovács Z; Szilágyi G
Orv Hetil; 1993 Oct; 134(42):2301-3. PubMed ID: 8233444
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
[TBL] [Abstract][Full Text] [Related]
12. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion.
Bates AS; Evans AJ; Jones P; Clayton RN
Clin Endocrinol (Oxf); 1995 Apr; 42(4):417-23. PubMed ID: 7750196
[TBL] [Abstract][Full Text] [Related]
13. Acromegaly and hyperprolactinemia in a patient with polyostotic fibrous dysplasia: dynamic endocrine studies and treatment with the somatostatin analogue octreotide.
Garcia MB; Koppeschaar HP; Lips CJ; Thijssen JH; Krenning EP
J Endocrinol Invest; 1994 Jan; 17(1):59-65. PubMed ID: 7911814
[TBL] [Abstract][Full Text] [Related]
14. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
[TBL] [Abstract][Full Text] [Related]
15. [Long-term treatment of acromegaly and gigantism with octreotide (SMS 201-995)].
Shimatsu A; Imura H; Irie M; Nakagawa S; Goto Y; Shimizu N; Takeda R; Kato Y; Saito S; Ibayashi H
Nihon Naibunpi Gakkai Zasshi; 1992 Feb; 68(2):89-99. PubMed ID: 1592144
[TBL] [Abstract][Full Text] [Related]
16. Acromegaly with normal IGF-1 levels probably due to poorly controlled diabetes mellitus.
Arihara Z; Sakurai K; Yamada S; Murakami O; Takahashi K
Tohoku J Exp Med; 2008 Dec; 216(4):325-9. PubMed ID: 19060447
[TBL] [Abstract][Full Text] [Related]
17. The GH-releasing hormone (GHRH) test in acromegaly before and after adenomectomy.
Giusti M; Lomeo A; Monachesi M; Mazzocchi G; Attanasio R; Sessarego P; Mignone D; Del Monte P; Giordano G
J Endocrinol Invest; 1987 Apr; 10(2):143-51. PubMed ID: 3108356
[TBL] [Abstract][Full Text] [Related]
18. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
19. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
Ezzat S; Ren SG; Braunstein GD; Melmed S
J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study.
Fredstorp L; Werner S
J Endocrinol Invest; 1993 Apr; 16(4):253-8. PubMed ID: 8514980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
